Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $9.40 - 0.03 (0.32%)
ExchangeNASDAQ
Volume20,524
Today's Open$9.41
Previous Close$9.43
Data as of 01/16/18 11:54 a.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $9.40 with a 52 week high of $15.00 and a 52 week low of $5.76.

Recent News

January 08, 2018

Nuvectra™ Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue

PLANO, Texas, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2017. Preliminary unaudited fourth quarter consolidated revenue is expected to be in the range of $11.5 to $12.0 million, compared to $4.2 million in the fourth quarter of 2016. Preliminary unaudited Algovita revenue for the fourth quarter of 2017 is expected to be

Read More >

January 03, 2018

Nuvectra Announces Analyst & Investor Meeting at NANS 2018

Event to Feature Leading Physician Presentations on Nuvectra’s Algovita system PLANO, Texas, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company will host an Analyst & Investor Meeting on Friday, January 12th during the 2018 North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas, NV. The meeting will feature presentations by leading neuromodulation physicians Giancarlo Barolat,

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Zack Kubow
investors@nuvectramed.com

Events
There are currently no events scheduled.